Clinical Trial Update: TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating TARGTEPO for anemia in chronic kidney disease and end-stage renal disease; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• TARGTEPO

Snippet

Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company | Conditions: Chronic Kidney Disease, End Stage Renal Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-10-30